(Q35124866)

6 August 2017

1 reference

title

The problems and challenges of immunotherapy in sepsis (English)

1 reference

6 August 2017

The Problems and Challenges of Immunotherapy in Sepsis* (English)

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

1 January 2024

0 references

1 reference

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

1 January 2024

author name string

Stanley A. Nasraway

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12740228

1 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0012369215330750?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

https://api.elsevier.com/content/article/PII:S0012369215330750?httpAccept=text/plain

1 January 2024

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

1 January 2024

1 reference

6 August 2017

volume

123

1 reference

6 August 2017

issue

5 Suppl

1 reference

6 August 2017

page(s)

451S-9S

1 reference

Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 January 2024

2

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Pathogenetic mechanisms of septic shock

1 January 2024

3

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

1 January 2024

Cardiogenic shock

4

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

1 January 2024

5

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy

1 January 2024

7

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 January 2024

8

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Sepsis research: we must change course

1 January 2024

9

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 January 2024

10

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment

1 January 2024

11

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

1 January 2024

12

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

CDP571, a humanized antibody to human tumor necrosis factor-alpha

1 January 2024

17

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

1 January 2024

18

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 January 2024

19

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 January 2024

20

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

1 January 2024

21

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

1 January 2024

23

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition

1 January 2024

25

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F: The Ramses study

1 January 2024

26

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 January 2024

30

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

1 January 2024

31

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

The pathogenesis of sepsis

1 January 2024

32

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation

1 January 2024

33

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Cytokine serum level during severe sepsis in human IL-6 as a marker of severity

1 January 2024

34

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines

1 January 2024

35

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

1 January 2024

Immunotherapy for sepsis

37

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.

1 January 2024

38

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Current understanding of sepsis

1 January 2024

39

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Interleukin-8 in sepsis: relation to shock and inflammatory mediators

1 January 2024

40

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis

1 January 2024

43

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma

1 January 2024

45

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock

1 January 2024

47

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Aminoguanidine selectively decreases cyclic GMP levels produced by inducible nitric oxide synthase

1 January 2024

48

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Elevation of systemic oxygen delivery in the treatment of critically ill patients.

1 January 2024

50

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Relative contribution of preload and afterload to the reduction in cardiac output caused by nitric oxide synthase inhibition with L-N(G)-methylarginine hydrochloride 546C88.

1 January 2024

51

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

1 January 2024

52

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients

1 January 2024

53

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Dear SIRS, I'm sorry to say that I don't like you

1 January 2024

54

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria?

1 January 2024

55

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

The uncertain value of the definition for SIRS. Systemic inflammatory response syndrome

1 January 2024

56

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Another negative clinical trial of a new agent for the treatment of sepsis: rethinking the process of developing adjuvant treatments for serious infections

1 January 2024

57

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Quality of health care. Part 6: The role of physicians in the future of quality management

1 January 2024

58

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome

1 January 2024

59

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 January 2024

60

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

1 January 2024

61

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis

1 January 2024

62

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

1 January 2024

63

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis

1 January 2024

64

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

1 January 2024

65

1 reference

https://api.crossref.org/works/10.1378/CHEST.123.5_SUPPL.451S

1 January 2024

Identifiers

1 reference

6 August 2017

1 reference